KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Notes Payables (2016 - 2025)

Historic Notes Payables for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$724.4 million.

  • Gsk's Notes Payables fell 23997.6% to -$724.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$724.4 million, marking a year-over-year decrease of 23997.6%. This contributed to the annual value of -$3.0 billion for FY2024, which is 18581.81% down from last year.
  • Latest data reveals that Gsk reported Notes Payables of -$724.4 million as of Q3 2025, which was down 23997.6% from -$2.7 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Notes Payables peaked at $4.9 billion during Q4 2021, and registered a low of -$7.4 billion during Q2 2023.
  • Moreover, its 5-year median value for Notes Payables was -$357.1 million (2021), whereas its average is -$943.2 million.
  • Per our database at Business Quant, Gsk's Notes Payables surged by 9436.96% in 2021 and then plummeted by 117904.71% in 2023.
  • Quarter analysis of 5 years shows Gsk's Notes Payables stood at $4.9 billion in 2021, then dropped by 4.51% to $4.6 billion in 2022, then fell by 24.68% to $3.5 billion in 2023, then tumbled by 186.35% to -$3.0 billion in 2024, then surged by 75.97% to -$724.4 million in 2025.
  • Its Notes Payables was -$724.4 million in Q3 2025, compared to -$2.7 billion in Q2 2025 and -$2.5 billion in Q1 2025.